Presenters: Kenneth J. Bloom, M.D., FCAP | Chief Medical Officer of Advanced Pathology and Genomic Services, Invicro
Matthew Silva, Ph.D. | CEO, Invicro
Where does the drug go? And what does it do? In drug discovery these are two big questions that hold various challenges. In the case of gene therapy, researchers need to address these questions for both the gene-carrying particle and the gene itself which provides further complications.
In this webinar we cover the challenges in answering these questions using current techniques and will introduce and demonstrate several multi-modality imaging approaches that addresses these challenges. These approaches, ranging from in vivo imaging to ex vivo tissue molecular imaging, provides a suite of comprehensive solutions to interrogate the bio-distribution, pharmacokinetics, pharmacodynamics and pharmacoexpression of the vector and the gene.
Dr. Bloom has more than 30 years of clinical experience and has been an early adopter of precision medicine. He is a renowned researcher and lecturer in pathology, cancer, telemedicine, and informatics.
Dr. Bloom recently joined Invicro as the CMO of advanced pathology and advanced genomic services. Prior to Invicro, he served as the President and head of oncology and immunotherapy at Human Longevity Inc., Chief Medical Officer of In Vitro Diagnostics at GE Healthcare, senior medical director at US Labs and director of laboratory operations at Rush Medical Center. Dr. Bloom has held a series of academic position as including Clinical Professor of Pathology at USC and CIO at Rush Cancer Center.
Dr. Silva is CEO of Invicro and leads the strategic vision and mission to support the the drug discovery and development community.
Dr. Silva holds a PhD in Biomedical Engineering from Worcester Polytechnic Institute and brings 17 years of diverse imaging experience from pharmaceutical and contract research organizations. Prior to Invicro, he was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the imaging and histopathology groups. Previously, he led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, focusing on the broad use of imaging biomarkers to support drug discovery and development.